TSE:MDP FY2026 EPS Forecast Lifted by Leede Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Leede Financial boosted their FY2026 EPS estimates for Medexus Pharmaceuticals in a note issued to investors on Wednesday, January 22nd. Leede Financial analyst D. Loe now expects that the company will post earnings of $0.29 per share for the year, up from their prior estimate of $0.22. Leede Financial has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

MDP has been the topic of several other reports. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a research report on Wednesday, January 8th. Stifel Nicolaus raised their target price on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Finally, Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. One equities research analyst has rated the stock with a buy rating and five have given a strong buy rating to the company. Based on data from MarketBeat.com, Medexus Pharmaceuticals presently has an average rating of “Strong Buy” and a consensus target price of C$5.58.

Medexus Pharmaceuticals Stock Up 10.1 %

Shares of MDP opened at C$4.92 on Friday. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56. The company’s fifty day moving average is C$3.25 and its two-hundred day moving average is C$2.72. The firm has a market cap of C$120.69 million, a PE ratio of 98.40 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.